The benefits of tyrosine kinase inhibitors (TKIs) for various forms of mutated NSCLC have been remarkable, as for example with osimertinib in first-line therapy of EGFR-mutated NSCLC, alectinib and larotrectinib for anaplastic lymphoma kinase gene (ALK) and neurotrophic tyrosine receptor kinase (NTRK) fusion-positive NSCLC, respectively.11-14 Molecularly guided immunotherapy has shown remarkable benefits across NSCLC settings.15-17. This evidence concerns the gene ALK and non-small cell lung carcinoma.